Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Gains from Investment Securities for 6 consecutive years, with $27.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 8738.43% to $27.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.2 million, a 8738.43% increase, with the full-year FY2022 number at $732395.0, up 20.09% from a year prior.
  • Gains from Investment Securities was $27.2 million for Q3 2025 at Inhibikase Therapeutics, up from $25.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $27.2 million in Q3 2025 to a low of $18039.0 in Q1 2024.
  • A 5-year average of $4.7 million and a median of $134215.5 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 96.78% in 2021, then skyrocketed 118139.34% in 2025.
  • Inhibikase Therapeutics' Gains from Investment Securities stood at $29839.0 in 2021, then surged by 156.88% to $76651.0 in 2022, then increased by 13.07% to $86669.0 in 2023, then soared by 255.42% to $308039.0 in 2024, then skyrocketed by 8738.43% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Gains from Investment Securities are $27.2 million (Q3 2025), $25.8 million (Q2 2025), and $21.3 million (Q1 2025).